Carteolol

Carteolol

Clinical data
Trade names	Ocupress
AHFS/Drugs.com	Professional Drug Facts
MedlinePlus	a601078
License data	US  DailyMed:  Carteolol
Routes of administration	Eye drops
ATC code	C07AA15 ( WHO ) S01ED05 ( WHO )
Legal status
Legal status	US: ℞-only In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	85%
Metabolism	Liver, active with 8-hydrocarteolol
Elimination half-life	6–8 hours
Excretion	Kidney (50–70%)
Identifiers
IUPAC name (RS)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydroquinolin-2(1H)-one
CAS Number	51781-06-7
PubChem CID	2583
IUPHAR/BPS	7142
DrugBank	DB00521  Y
ChemSpider	2485  Y
UNII	8NF31401XG
KEGG	D07624  Y
ChEBI	CHEBI:3437  Y
ChEMBL	ChEMBL839  Y
CompTox Dashboard (EPA)	DTXSID3022746
Chemical and physical data
Formula	C16H24N2O3
Molar mass	292.379 g·mol−1
3D model (JSmol)	Interactive image
Chirality	Racemic mixture
SMILES O=C2Nc1cccc(OCC(O)CNC(C)(C)C)c1CC2
InChI InChI=1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20) Y Key:LWAFSWPYPHEXKX-UHFFFAOYSA-N Y
(verify)

Carteolol is a non-selective beta blocker used to treat glaucoma. It is administered in the form of eye drops.^{[ citation needed ]}

Carteolol was patented in 1972 and approved for medical use in 1980. ^[1]

Pharmacology

Pharmacodynamics

Carteolol is a beta blocker, or an antagonist of the β-adrenergic receptors. ^[2] It is selective for the β₁-adrenergic receptor and has intrinsic sympathomimetic activity. ^[2] Carteolol has also been found to act as a serotonin 5-HT_1A and 5-HT_1B receptor antagonist in addition to being a beta blocker. ^[3]

Pharmacokinetics

Carteolol is classified as a beta blocker with low lipophilicity and hence lower potential for crossing the blood–brain barrier. ^[2] This in turn may result in fewer effects in the central nervous system as well as a lower risk of neuropsychiatric side effects. ^[2]

Chemistry

The experimental log P of carteolol is 1.1 and its predicted log P ranges from 0.99 to 2.39. ^{[4] [5] [6] [7]} It is a hydrophilic or low-lipophilicity beta blocker. ^{[7] [2]}

Society and culture

Brand names

Brand names of carteolol include Arteolol, Arteoptic, Calte, Cartéabak, Carteol, Cartéol, Cartrol, Elebloc, Endak, Glauteolol, Mikelan, Ocupress, Poenglaucol, Singlauc, and Teoptic.

References

1. Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 460. ISBN   978-3-527-60749-5.
2. Cojocariu SA, Maștaleru A, Sascău RA, Stătescu C, Mitu F, Leon-Constantin MM (February 2021). "Neuropsychiatric Consequences of Lipophilic Beta-Blockers". Medicina (Kaunas). 57 (2): 155. doi: 10.3390/medicina57020155 . PMC   7914867 . PMID   33572109.
3. Langlois M, Brémont B, Rousselle D, Gaudy F (January 1993). "Structural analysis by the comparative molecular field analysis method of the affinity of beta-adrenoreceptor blocking agents for 5-HT1A and 5-HT1B receptors". European Journal of Pharmacology. 244 (1): 77–87. doi:10.1016/0922-4106(93)90061-d. PMID   8093601.
4. "Carteolol". PubChem. Retrieved 10 July 2025.
5. "C16H24N2O3". ChemSpider. 10 June 2024. Retrieved 10 July 2025.
6. "Carteolol: Uses, Interactions, Mechanism of Action". DrugBank Online. 19 September 2006. Retrieved 10 July 2025.
7. Mannhold R (February 2005). "The impact of lipophilicity in drug research: a case report on beta-blockers". Mini Rev Med Chem. 5 (2): 197–205. doi:10.2174/1389557053402701. PMID   15720289.

Further reading

• El-Kamel A, Al-Dosari H, Al-Jenoobi F (2006). "Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride". Drug Delivery. 13 (1): 55–59. doi: 10.1080/10717540500309073 . PMID   16401594. S2CID   30222292.
• Kuwahara K, Oizumi N, Fujisawa S, Tanito M, Ohira A (March 2005). "Carteolol hydrochloride protects human corneal epithelial cells from UVB-induced damage in vitro". Cornea. 24 (2): 213–220. doi:10.1097/01.ico.0000141232.41343.9d. PMID   15725891. S2CID   20523541.
• Trinquand C, Romanet JP, Nordmann JP, Allaire C (February 2003). "[Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]". Journal Français d'Ophtalmologie. 26 (2): 131–136. PMID   12660585.